Does the Clinical and Therapeutic Profile of Eprosartan Contribute to End Organ Protection?

Journal of Clinical and Basic Cardiology

Ram CVS¹ 

[1] $$

关键词: Angiotensin-II-Rezeptorblockade;    Eprosartan;    Hypertonie;    Kardiologie;    MOSES-Studie;    Schlaganfall;    angiotensin receptor blockade;    cardiology;    Eprosartan;    hypertension;    MOSES trial;    stroke;   

DOI  :  

学科分类：心脏病和心血管学

来源: Krause & Pachernegg GmbH

【 摘 要 】

Systemic hypertension is a major risk factor for premature morbidity and mortality. The diseases caused by hypertension can be serious and deadly.Therefore, various guidelines consistently recommend lower target levels of blood pressure for intervention. One important mechanism sustaining hypertension and causing target organ damage is the renin-angiotensin system. Hence, interruption of this system with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) offers a useful avenue to lower the cardiovascular risk. Of particular benefit are ARBs, which not only lower the blood pressure effectively, but also cause no side effects. Thus, ARBs provide a logical and physiological approach to treat hypertension. Among all the available ARBs, eprosartan possesses a unique mechanism of action in inhibiting both the reninangiotensinsystem and also the sympathetic nervous system; this dual mechanism of action offers distinct physiological and pharmacologicalbenefits to the patients. Studies have shown that eprosartan is not only effective in controlling hypertension, but also provides remarkable targetorgan protection.

【 授权许可】

Unknown